Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Y-mAbs Therapeutics, Inc. filings document the company’s biopharmaceutical business, common stock, governance and completed transition from Nasdaq-listed issuer to deregistered reporting status. Recent 8-K reports cover operating results, material agreements, shareholder votes and completion of the merger process.
Form 25 records removal of the company’s common stock from Nasdaq listing and registration under Section 12(b) of the Exchange Act. Form 15 records termination of Section 12(g) registration and suspension of reporting duties under Sections 13 and 15(d), with the filing identifying one holder of record as of the notice date.
Y-mAbs Therapeutics director and 10% owner Johan Wedell-Wedellsborg reported multiple disposals tied to a completed merger. On September 16, 2025, Purchaser completed a tender offer and merged Y-mAbs into an indirect wholly owned subsidiary of Perseus BidCo US, Inc., with each outstanding share cancelled for $8.60 cash per share. The reporting person’s direct and indirect common shares, restricted stock units and stock options were cancelled and converted into cash payments under the Merger Agreement: ordinary shares and RSUs were exchanged for $8.60 per share, while options were cashed out for the excess of $8.60 over each exercise price; options with exercise prices at or above $8.60 were cancelled without consideration. The Form 4 reflects zero continuing share ownership.
John LaRocca, SVP, General Counsel & Secretary of Y-mAbs Therapeutics (YMAB), reported transactions tied to the companys merger completed on 09/16/2025. Pursuant to the Merger Agreement, outstanding restricted stock units (RSUs) and stock options were cancelled and converted into cash payments: RSUs (21,500) were settled for cash at $8.60 per share, and outstanding options were converted into cash equal to the excess of $8.60 over the option exercise price where applicable. Options with an exercise price equal to or above $8.60 were cancelled for no consideration. The filing shows zero shares and zero options beneficially owned by the reporting person after the transactions, and that Y-mAbs became an indirect wholly owned subsidiary of the acquiring parent.
Healy James, a Sofinnova-affiliated director of Y-mAbs Therapeutics (YMAB), reported transactions tied to the company's merger. On 09/16/2025 Purchaser completed a tender offer and merged with the issuer, and each outstanding common share was cancelled for $8.60 cash per share. The reporting person disposed of 31,603 shares and 25,080 restricted stock units were converted into cash in connection with the merger. Outstanding stock options were cancelled and converted into cash equal to the excess of $8.60 over each option's exercise price; options with exercise prices at or above $8.60 were cancelled for no consideration.
Y-mAbs Therapeutics filed a series of Form S-8 registration statements registering common stock for employee equity plans. The filings register: 2,799,373 shares for options under the Amended and Restated 2015 Equity Incentive Plan; 2,122,127 shares for the 2018 Equity Incentive Plan; 578,500 shares for options under the 2018 EIP; 700,000 shares for the 2018 Employee Stock Purchase Plan; 8,078,887 shares (3/30/2023); 1,746,884 shares (2/29/2024); and 1,799,532 shares (3/4/2025) under the 2018 EIP.
Y-mAbs Therapeutics filed a post-effective amendment to registration statements on Form S-8 covering multiple employee equity plans. The filing lists prior Form S-8 registrations that reserve specific share amounts: 2,799,373 shares tied to the 2015 plan options and 2018 plan allocations, 2,122,127 shares under the 2018 Equity Incentive Plan, 578,500 shares for outstanding options under the 2018 plan, 700,000 shares for the 2018 Employee Stock Purchase Plan, and additional 2018 EIP authorizations of 8,078,887, 1,746,884 and 1,799,532 shares on later Forms S-8.
Y-mAbs Therapeutics, Inc. filed post-effective amendments to multiple Form S-8 registration statements to register shares for employee equity plans. The filing lists prior Form S-8 registrations: 2,799,373 shares (2019 filing), 8,078,887 shares (2023 filing), 1,746,884 shares (2024 filing) and 1,799,532 shares (2025 filing), each authorized for issuance under the company's 2015 and 2018 equity plans and an employee stock purchase plan.
Y-mAbs Therapeutics announced a merger agreement that converts outstanding equity awards into cash at the Effective Time. The Agreement and Plan of Merger dated August 4, 2025 is referenced and exhibits including the amended certificate and bylaws are filed. All stock options outstanding immediately before the Effective Time are cancelled and converted into a cash payment equal to the number of shares covered multiplied by the excess of the Merger Consideration over the option exercise price; options with an exercise price at or above the Merger Consideration are cancelled for no consideration. Restricted stock units (RSU Awards) convert into cash equal to the shares issuable multiplied by the Merger Consideration, while performance-based RSUs (PSU Awards) convert into cash based on the maximum number of shares issuable multiplied by the Merger Consideration. The filing references the merger agreement and supporting exhibits but does not disclose the numeric Merger Consideration within the provided text.
Y-mAbs Therapeutics, Inc. submitted a Form 25 notification indicating the company’s class of securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies Nasdaq as the exchange and confirms that the Exchange and the Issuer have followed the procedural rules governing removal or voluntary withdrawal under the Securities Exchange Act. The document is a short procedural notice and does not include financial results, reasons for the removal, effective delisting date, or details about alternate trading arrangements.
Y-mAbs Therapeutics, Inc. reports that the tender offer by Perseus BidCo US, Inc. to acquire the company has closed at $8.60 in cash per share. As of the offer’s expiration at one minute after 11:59 p.m. Eastern time on September 15, 2025, 39,827,138 shares had been validly tendered and not withdrawn, representing approximately 87.22% of the then outstanding shares, satisfying the minimum tender condition.
The purchaser accepted all validly tendered shares, and the merger was completed on September 16, 2025 under Section 251(h) of the DGCL, with Y-mAbs surviving as a wholly owned subsidiary of the buyer’s parent. Following the merger, Y-mAbs shares ceased trading on the Nasdaq Global Select Market and will be delisted, and steps will be taken to terminate registration and suspend reporting obligations under the Exchange Act.